Table 2.
Demographic and clinical data of the study groups.
| Group | EC | PD-FoG | PD+FoG− | PD+FoG+ |
|---|---|---|---|---|
| f/m | 5/3 | 3/3 | 0/4 | 0/4 |
| Age [y] | 63.0 ± 8.5 | 69.8 ± 8.1 | 66.0 ± 8.3 | 66.6 ± 8.8 |
| BMI | 25.1 ± 3.1 | 26.0 ± 4.2 | 26.0 ± 2.3 | 26.5 ± 6.7 |
| Disease duration | N/A | 10.2 ± 4.7 | 8.0 ± 4.4 | 12.8 ± 5.6 |
| L-dopa equivalent | ||||
| daily dose (LEDD) [mg] | N/A | 872 ± 253 | 1250 ± 230 | 1448 ± 24 |
| MoCA | 25.8 ± 2.3 | 23.1 ± 5.8 | 21.5 ± 3.1 | 22.7 ± 2.2 |
| UPDRS-Motor | ||||
| score (Part III) | N/A | 15.5 ± 6.9 | 20.0 ± 8.2 | 16.5 ± 4.7 |
Elderly controls (EC), participants with Parkinson’s disease that do not show freezing of gait (PD-FoG), participants with Parkinson’s disease that usually have FoG but did not show it during the experiment (PD+FoG−), and participants with Parkinson’s disease and FoG during the experiment (PD+FoG+). Gender f/m female/male, BMI body mass index (in kg/m2), MoCA Montreal Cognitive Assessment71, UPDRS Unified Parkinson’s Disease Rating Scale72. Reported are means and standard deviations; the differences between the groups are not significant, except for gender, and LEDD between PD-FoG and PD+FoG+. We note that LEDD was not available for all subjects.